75 related articles for article (PubMed ID: 2925220)
1. [Therapy of pancreatic carcinoma with the monoclonal antibody BW 494/32: first clinical results].
Friess H; Büchler M; Schulz G; Beger HG
Immun Infekt; 1989 Feb; 17(1):24-6. PubMed ID: 2925220
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].
Büchler M; Kübel R; Malfertheiner P; Friess H; Schulz G; Bosslet K; Beger HG
Dtsch Med Wochenschr; 1988 Mar; 113(10):374-80. PubMed ID: 3349938
[TBL] [Abstract][Full Text] [Related]
3. [Monoclonal antibodies in the therapy of non-resectable pancreatic cancers. Initial experiences].
Muhrer KH; Büchler M; Lucks A; Süss D; Klapdor R; Schulz G
Chirurg; 1988 May; 59(5):328-34. PubMed ID: 3396446
[TBL] [Abstract][Full Text] [Related]
4. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects.
Tempero MA; Sivinski C; Steplewski Z; Harvey E; Klassen L; Kay HD
J Clin Oncol; 1990 Dec; 8(12):2019-26. PubMed ID: 2121912
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494.
Schulz G; Büchler M; Muhrer KH; Klapdor R; Kübel R; Harthus HP; Madry N; Bosslet K
Int J Cancer Suppl; 1988; 2():89-94. PubMed ID: 3162451
[TBL] [Abstract][Full Text] [Related]
7. Immunological tailoring of monoclonal antibodies for immunotherapy of pancreatic carcinoma.
Bosslet K; Döring N; Seemann G; Schulz G; Sedlacek HH
Int J Cancer Suppl; 1988; 2():85-8. PubMed ID: 3162450
[TBL] [Abstract][Full Text] [Related]
8. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.
Weiner LM; Steplewski Z; Koprowski H; Litwin S; Comis RL
Cancer Res; 1988 Feb; 48(4):1042-6. PubMed ID: 3123051
[TBL] [Abstract][Full Text] [Related]
9. Percolation and binding of MAB BW 494 to pancreatic carcinoma tissues during high dose immunotherapy and consequences for future therapy modalities.
Bosslet K; Keweloh HC; Hermentin P; Muhrer KH; Sedlacek HH; Schulz G
Behring Inst Mitt; 1990 Dec; (87):68-75. PubMed ID: 2096821
[TBL] [Abstract][Full Text] [Related]
10. Studies of pancreatic cancer utilizing monoclonal antibodies.
Büchler M; Friess H; Malfertheiner P; Schultheiss KH; Muhrer KH; Kraemer HP; Beger HG
Int J Pancreatol; 1990; 7(1-3):151-7. PubMed ID: 1964470
[TBL] [Abstract][Full Text] [Related]
11. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma.
Weiner LM; Harvey E; Padavic-Shaller K; Willson JK; Walsh C; LaCreta F; Khazaeli MB; Kirkwood JM; Haller DG
J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):110-6. PubMed ID: 8318495
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of CO17-1A monoclonal antibody.
Lobuglio AF; Saleh M; Peterson L; Wheeler R; Carrano R; Huster W; Khazaeli MB
Hybridoma; 1986 Jul; 5 Suppl 1():S117-23. PubMed ID: 3488950
[TBL] [Abstract][Full Text] [Related]
14. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results.
Sindelar WF; Maher MM; Herlyn D; Sears HF; Steplewski Z; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S125-32. PubMed ID: 3744377
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM).
Paul AR; Engstrom PF; Weiner LM; Steplewski Z; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S171-4. PubMed ID: 3527946
[TBL] [Abstract][Full Text] [Related]
16. Immunoscintigraphy and radioimmunotherapy in patients with pancreatic carcinoma.
Montz R; Klapdor R; Rothe B; Heller M
Nuklearmedizin; 1986 Dec; 25(6):239-44. PubMed ID: 3027672
[TBL] [Abstract][Full Text] [Related]
17. Imaging of pancreatic and colorectal cancer using antibody fragments: a preliminary evaluation.
Ballantyne KC; Perkins AC; Selby C; Wastie ML; Hardcastle JD
Eur J Surg Oncol; 1988 Oct; 14(5):393-8. PubMed ID: 3181442
[TBL] [Abstract][Full Text] [Related]
18. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer.
Tempero MA; Pour PM; Uchida E; Herlyn D; Steplewski Z
Hybridoma; 1986 Jul; 5 Suppl 1():S133-8. PubMed ID: 3744378
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
